By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Blueprint Medicines 



Cambridge  Massachusetts  02140  U.S.A.
Phone: 617-585-2033 Fax: n/a


SEARCH JOBS


Industry
Biotechnology






Company News
As Market Froths, Blueprint Medicines (BPMC) Debuts $147 Million IPO for Massachusetts' Biggest Recent IPO 4/30/2015 6:14:42 AM
Blueprint Medicines Presents New Preclinical Data Demonstrating Its Drug Candidate BLU-554 Induces Significant Tumor Regression In Models Of Hepatocellular Carcinoma 4/24/2015 10:47:38 AM
Blueprint Medicines Presents New Preclinical Data Demonstrating Significant Anti-Tumor Activity Of BLU-285 In Treatment-Resistant GIST And On Novel Cancer Drug Targets 4/20/2015 6:07:42 AM
Fidelity CEO Uses Personal Fortune to Bet on Cancer Related IPOs Like Coherus, Adaptimmune and Blueprint Medicines 4/10/2015 6:06:18 AM
Blueprint Medicines To Present New Preclinical Data On BLU-285 In Treatment-Resistant GIST And On Novel Cancer Drug Targets At Upcoming American Association for Cancer Research Annual Meeting 4/8/2015 7:43:21 AM
Blueprint Medicines Files Registration Statement for Proposed Initial Public Offering 3/24/2015 6:58:28 AM
With Alexion (ALXN) Deal in Hand, Blueprint Medicines Preps for $100 Million IPO 3/24/2015 6:06:57 AM
Blueprint Medicines Appoints Charles A. Rowland, Jr. To Its Board Of Directors 3/23/2015 7:23:18 AM
Blueprint Medicines Publishes Preclinical Proof-Of-Concept Data On Promising New Therapy For Patients With Genomically Defined Hepatocellular Carcinoma 3/16/2015 7:35:42 AM
Blueprint Medicines Strikes $265 Million Deal With Alexion Pharmaceuticals Inc. (ALXN) 3/3/2015 7:26:15 AM
1234
//-->